Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin
Primary Purpose
Postpartum Hemorrhage
Status
Completed
Phase
Phase 3
Locations
India
Study Type
Interventional
Intervention
Misoprostol
Oxytocin
Sponsored by
About this trial
This is an interventional prevention trial for Postpartum Hemorrhage focused on measuring Misoprostol, oxytocin, postpartum blood loss, hemoglobin
Eligibility Criteria
Inclusion Criteria:
- Women with a gestational age >28weeks
- singleton pregnancy with cephalic presentation anticipating a normal spontaneous vaginal delivery (including episiotomy)
- a haemoglobin ≥ 8g/dl upon presentation who were admitted to labour room in the KLE teaching hospital attached to J N Medical College, Belgaum
Exclusion Criteria:
- Women with pregnancy induced hypertension
- antepartum haemorrhage
- previous caesarean section or presence of uterine scar
- diagnosed chorioamnionitis
- oxytocin induction or augmentation of labour
- intrauterine death
- diagnosed medical disorders (such as diabetes, cardiac, renal and hepatic diseases, etc.) or those in active labour (defined as >4 cm dilatation)
Sites / Locations
- Jawaharlal Nehru Medical College
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sublingual misoprostol
Oxytocin
Arm Description
400 µg powdered misoprostol administered sublingually; IM placebo
10 IU IM oxytocin; placebo powder
Outcomes
Primary Outcome Measures
mean blood loss
Blood loss was objectively measured using the BRASSS-V DrapeTM, placed under the buttock before the delivery. The calibrated blood collection receptacle was opened after the delivery and drainage of amniotic fluid. Blood collected in the drape was transferred to measuring jar with 10 ml calibrations for accuracy. Blood soaked swabs were weighed in grams, and the known dry weight of the swabs was subtracted; this volume was added to the drape's measured blood volume (assuming 1 gm equivalence with 1 ml).
postpartum hemorrhage (Blood loss >500 mls)
Blood loss was objectively measured using the BRASSS-V DrapeTM, placed under the buttock before the delivery. The calibrated blood collection receptacle was opened after the delivery and drainage of amniotic fluid. Blood collected in the drape was transferred to measuring jar with 10 ml calibrations for accuracy. Blood soaked swabs were weighed in grams, and the known dry weight of the swabs was subtracted; this volume was added to the drape's measured blood volume (assuming 1 gm equivalence with 1 ml).
Secondary Outcome Measures
The percent of women experiencing a ≥10% postpartum decline in haemoglobin
Hemoglobin was obtained at presentation for delivery and again between 12 and 48 hours after delivery.
Medication side effects
Self reported side effects including nausea, vomiting, diarrhoea, abdominal pain, shivering and elevated temperature
Full Information
NCT ID
NCT01373359
First Posted
June 9, 2011
Last Updated
June 13, 2011
Sponsor
Jawaharlal Nehru Medical College
Collaborators
Cipla Ltd., AstraZeneca
1. Study Identification
Unique Protocol Identification Number
NCT01373359
Brief Title
Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin
Official Title
A One Year Double Blind Randomized Controlled Trial of Sublingual Misoprostol (400 µg) Versus Intramuscular Oxytocin (10 IU) in the Prevention of Postpartum Bloodloss at KLE Hospital, Belgaum
Study Type
Interventional
2. Study Status
Record Verification Date
January 2008
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Jawaharlal Nehru Medical College
Collaborators
Cipla Ltd., AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sublingual misoprostol produces rapid peak concentration and is more effective than oral misoprostol for prevention of excessive postpartum bleeding. The study hypothesis was to test whether women receiving sublingual misoprostol for prevention of postpartum hemorrhage have 30 ml less average blood loss than women receiving oxytocin, the standard of care for prevention of postpartum hemorrhage. We conducted a Double blind randomized controlled trial of .652 consenting, eligible pregnant women admitted to the labor room of the teaching hospital at J N Medical College, Belgaum, India. Women participating in the study were assigned by computer generated randomization to receive the study medications and placebos within one minute after clamping and cutting the umbilical cord. We also looked at the drugs effects on postpartum blood loss at or above ≥500 ml (considered hemorrhage), and the percent of women experiencing more than a 10% decline in haemoglobin, and reported drug side effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage
Keywords
Misoprostol, oxytocin, postpartum blood loss, hemoglobin
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
652 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sublingual misoprostol
Arm Type
Experimental
Arm Description
400 µg powdered misoprostol administered sublingually; IM placebo
Arm Title
Oxytocin
Arm Type
Active Comparator
Arm Description
10 IU IM oxytocin; placebo powder
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
400 µg sublingual misoprostol
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Intervention Description
10 IU IM
Primary Outcome Measure Information:
Title
mean blood loss
Description
Blood loss was objectively measured using the BRASSS-V DrapeTM, placed under the buttock before the delivery. The calibrated blood collection receptacle was opened after the delivery and drainage of amniotic fluid. Blood collected in the drape was transferred to measuring jar with 10 ml calibrations for accuracy. Blood soaked swabs were weighed in grams, and the known dry weight of the swabs was subtracted; this volume was added to the drape's measured blood volume (assuming 1 gm equivalence with 1 ml).
Time Frame
2 hours after delivery
Title
postpartum hemorrhage (Blood loss >500 mls)
Description
Blood loss was objectively measured using the BRASSS-V DrapeTM, placed under the buttock before the delivery. The calibrated blood collection receptacle was opened after the delivery and drainage of amniotic fluid. Blood collected in the drape was transferred to measuring jar with 10 ml calibrations for accuracy. Blood soaked swabs were weighed in grams, and the known dry weight of the swabs was subtracted; this volume was added to the drape's measured blood volume (assuming 1 gm equivalence with 1 ml).
Time Frame
2 hours after delivery
Secondary Outcome Measure Information:
Title
The percent of women experiencing a ≥10% postpartum decline in haemoglobin
Description
Hemoglobin was obtained at presentation for delivery and again between 12 and 48 hours after delivery.
Time Frame
At presentation for delivery and 12-48 hours after delivery
Title
Medication side effects
Description
Self reported side effects including nausea, vomiting, diarrhoea, abdominal pain, shivering and elevated temperature
Time Frame
2 hours after delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women with a gestational age >28weeks
singleton pregnancy with cephalic presentation anticipating a normal spontaneous vaginal delivery (including episiotomy)
a haemoglobin ≥ 8g/dl upon presentation who were admitted to labour room in the KLE teaching hospital attached to J N Medical College, Belgaum
Exclusion Criteria:
Women with pregnancy induced hypertension
antepartum haemorrhage
previous caesarean section or presence of uterine scar
diagnosed chorioamnionitis
oxytocin induction or augmentation of labour
intrauterine death
diagnosed medical disorders (such as diabetes, cardiac, renal and hepatic diseases, etc.) or those in active labour (defined as >4 cm dilatation)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M B Bellad, M.D.
Organizational Affiliation
Jawaharlal Nehru Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jawaharlal Nehru Medical College
City
Belgaum
State/Province
Karnataka
ZIP/Postal Code
590010
Country
India
12. IPD Sharing Statement
Learn more about this trial
Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin
We'll reach out to this number within 24 hrs